睾酮棕榈酸酯 | 991-20-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 睾酮棕榈酸酯
• 中文别名: 巴比妥N-葡萄糖苷
• 英文名称: testosterone palmitate
• 英文别名: [(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] hexadecanoate
• CAS: 991-20-8
• 化学式: C₃₅H₅₈O₃
• 分子量: 526.844
• InChiKey: OKFBXYQPCPWWRP-SHDAAXGTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  11.2
• 重原子数：
  38
• 可旋转键数：
  16
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  棕榈酸酐 、 睾酮 以 吡啶 为溶剂， 反应 3.0h， 生成 睾酮棕榈酸酯
  参考文献：
  名称：

  Non-polar extracts of serum from males contain covert radioimmunoassayable testosterone

  摘要：

  Non-polar extracts of sera from human males contain immunoreactive testosterone in a form that is released by mild alkaline hydrolysis. The non-polar derivative shows no immunoreactivity with testosterone antibody prior to hydrolysis. Hydrolyzed non-polar serum extracts from ten adult male volunteers contained 2.0 +/- 0.8 (SD) ng/mL of testosterone. Neither non-polar serum extracts of normal females nor a water blank substituted for non-polar extract of serum yields any immunoreactive testosterone after alkaline hydrolysis. Testosterone palmitate hydrolyzed alone or after addition to non-polar extract of serum yields the expected quantities of radioimmunoassayable testosterone. Previously described conjugates of testosterone are polar and are neither extractable by petroleum ether nor hydrolyzable by alkali. These observations suggest that fatty acid esters of testosterone may be present in serum of human males.

  DOI：

  10.1016/0039-128x(89)90001-9

文献信息

• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• Steroidal Compositions
  申请人：Giliyar Chandrashekar

  公开号：US20100173882A1

  公开（公告）日：2010-07-08

  Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein.

  本文提供了含有类固醇的组合物，适合为个体提供治疗有效量的至少一种类固醇。本文还提供了含有睾酮和/或睾酮衍生物的组合物，适合在一段时间内提供治疗有效且安全的睾酮量。此外，本文还提供了通过向个体施用本文所述的组合物来治疗雄激素和/或睾酮缺乏症的方法。
• STEROIDAL COMPOSITIONS
  申请人：Giliyar Chandrashekar

  公开号：US20120322780A1

  公开（公告）日：2012-12-20

  Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein.

  本文提供一些含有类固醇成分的组合物，适用于向个体提供治疗有效量的至少一种类固醇。本文还提供了含有睾酮和/或睾酮衍生物的组合物，适用于在一段时间内提供治疗有效且安全的睾酮量。此外，本文还提供了通过向个体施用本文所述的组合物来治疗雄激素和/或睾酮缺乏的方法。
• Pharmaceutical compositions containing higher alcohols for the treatment of prostatic pathologies
  申请人：CONSIGLIO NAZIONALE DELLE RICERCHE

  公开号：EP0287000A1

  公开（公告）日：1988-10-19

  Pharmaceutical compositions containing as the active principle the alcoholic fraction obtained from the total lipophilic extract of Serenoa repens fruits, after al­kaline hydrolysis and extraction with water immiscible solvents. The extract is endowed with a better antiandrogenic activity in comparison to the total lipophilic extract.

  药用复方制剂，其活性成分是从 Serenoa repens 果实的总亲油提取物中提取的酒精馏分，经过碱性水解和水不溶性溶剂萃取而成。 与亲脂总萃取物相比，该萃取物具有更好的抗雄激素活性。
• Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
  申请人：Marius Pharmaceuticals LLC

  公开号：US10576089B2

  公开（公告）日：2020-03-03

  A formulation for drug delivery, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of a lipophilic therapeutic agent by formulation with sterols and/or sterol esters, resulting in higher bioavailability of a therapeutic agent administered to a subject in need of such therapeutic agent. The formulation contains a therapeutic agent and a sterol or sterol ester, and can, optionally, further contain a solubilizer and/or an enhancing agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.

  一种用于给药的制剂，通过与甾醇和/或甾醇酯配制，可增强对亲脂性治疗剂的溶解度、稳定性、吸收、代谢和/或药代动力学特征的调节，从而提高给需要此类治疗剂的受试者施用的治疗剂的生物利用度。制剂中含有一种治疗剂和一种甾醇或甾醇酯，还可选择进一步含有增溶剂和/或增强剂。此外，还描述了含有这些制剂的药物组合物以及制剂和药物组合物的制造方法和使用方法。当治疗剂包括睾酮或睾酮酯时，本公开的制剂可用于最大限度地减少双氢睾酮的合成。